The global insulin pen packaging market is entering a decade of steady expansion, driven by the surging global prevalence of diabetes and the rising shift toward convenient, portable, and patient-friendly insulin delivery systems. According to recent industry estimates, the market is projected to grow from USD 1.2 billion in 2025 to USD 2.1 billion by 2035, registering a CAGR of 5.1% during the forecast period. As insulin pens continue to replace traditional syringes and vials, effective and high-performance packaging has become essential to ensuring safety, dosing accuracy, and adherence.
Market Overview: A Specialized Yet Critical Segment of Diabetes Care
Although insulin pen packaging forms a relatively niche segment representing 2–4% of the insulin delivery devices industry its importance is undeniable as global diabetes cases surge. Insulin pens dominate the injection pen segment, and their packaging accounts for 2–3% of the category’s overall share. Within the broader pharmaceutical packaging ecosystem, insulin injector packaging holds a modest under-1% share, reflecting the wide diversity of applications in healthcare packaging.
Despite its small base, rapid growth in smart insulin administration, connected devices, patient-centric care, and home-based treatment is pushing manufacturers to innovate. In emerging smart medical device packaging, insulin pens hold a niche share of under 2%, attributed to early adoption stages of digital insulin systems.
Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates – https://www.futuremarketinsights.com/reports/sample/rep-gb-22384
Industry Milestone: SCHOTT Pharma Introduces New RTU Cartridge
Marking a notable advancement in 2025, SCHOTT Pharma unveiled a 1.5 ml ready-to-use (RTU) glass cartridge compatible with Ypsomed’s UnoPen® platform, reinforcing innovation in injectable drug packaging. This complements the earlier development of the 10 ml cartriQ® cartridge for large-volume injectors, reflecting heightened collaboration to enhance precision, sterility, and reliability in diabetes care packaging solutions.
Top Investment and Growth Segments
Dual Chamber Packaging Leads with 54% Share
Dual chamber insulin pens—designed to allow precise dosing and compatibility with combination therapies—are set to hold 54% of the packaging type share in 2025. Major industry players such as BD and Sanofi are heavily investing in enhancing usability, safety mechanisms, and dosing reliability.
Diabetes Care Dominates End-Use with 71% Share
With rising global diabetes incidence and a shift to home-based diabetes management, the diabetes care segment is projected to command 71% share. Innovations from Novo Nordisk, Eli Lilly, and Sanofi are supporting widespread adoption of advanced delivery systems, strengthening packaging demand.
Plastic Emerges as the Top Material with 60% Share
Affordable, versatile, and lightweight, plastic remains the leading material, holding a 60% market share in 2025. Companies like Gerresheimer and SCHOTT are scaling up production of high-quality plastic components featuring advanced barrier properties, improved sterility profiles, and tamper-proof functionality.
Market Dynamics: What’s Driving and Hindering Growth
Rising Diabetes Rates Spark Demand for Smart and Connected Packaging
Connected insulin pens, real-time dose tracking, and tamper-evident smart features are reshaping packaging requirements. As endocrinologists and clinicians prioritize adherence and glycemic precision, demand for digitally enabled, prefilled cartridges continues to increase. National reimbursement policies are accelerating adoption of smart systems across several high-growth markets.
Regulatory Barriers and Price Pressures Remain Key Challenges
Despite strong growth prospects, the industry is constrained by complex regulatory compliance requirements such as ISO 11607 and USP <1207>, resulting in longer validation cycles and high operating costs. Recycling challenges and mixed-material components add further pressure as global markets move toward sustainable healthcare packaging.
Country-Level Growth Forecast (2025–2035)
| Country | CAGR |
| China | 6.8% |
| India | 6.5% |
| Japan | 6.1% |
| United States | 5.0% |
| United Kingdom | 4.8% |
Countries like China and India are emerging as global manufacturing hubs, fueled by rising diabetes prevalence, enhanced healthcare procurement, and growth in contract packaging capacity. Meanwhile, OECD regions such as the US, UK, and Japan maintain steady growth supported by stable reimbursement systems and strong regulatory frameworks.
Regional Insights
United States
The U.S. market is growing at 5% CAGR, supported by smart insulin pen adoption, tamper-proof packaging formats, and ongoing investments by leading manufacturers.
United Kingdom
Projected to grow at 4.8% CAGR, with strong emphasis on recyclable, eco-conscious materials and ergonomic packaging for improved patient compliance.
China
The fastest-growing market at 6.8% CAGR, driven by smart-device adoption, investment in healthcare infrastructure, and expanding manufacturing capacity.
India
Growing at 6.5% CAGR, supported by improved diabetes care access, export-oriented packaging production, and rising preference for portable insulin delivery.
Japan
Expected to grow at 6.1% CAGR, driven by an aging population and demand for high-clarity, premium materials such as cyclic olefins.
Competitive Landscape
The market features a semi-fragmented structure led by global leaders:
- Novo Nordisk
- Eli Lilly
- Sanofi
- Gerresheimer
- Schott
- Becton Dickinson
- F. Hoffmann-La Roche
- Syringe Manufacturing Co.
- Medtronic
Leading equipment manufacturers such as Syntegon, AAE, Bausch + Ströbel, AIPAK, and Shanghai Marya Pharmatech are accelerating automation and precision engineering in insulin pen assembly lines.
Recent Developments
- Embecta, producing over 8 billion syringes and insulin pen needles annually, announced strategic restructuring due to financial headwinds.
- Cipla, in partnership with MannKind, gained regulatory approval to market Afrezza inhalable insulin in India—marking a shift toward alternative insulin delivery methods.
Why FMI: https://www.futuremarketinsights.com/why-fmi
About Future Market Insights (FMI)
Future Market Insights, Inc. (FMI) is an ESOMAR-certified, ISO 9001:2015 market research and consulting organization, trusted by Fortune 500 clients and global enterprises. With operations in the U.S., UK, India, and Dubai, FMI provides data-backed insights and strategic intelligence across 30+ industries and 1200 markets worldwide.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
